Skip to main content
. 2017 Jan 12;45(6):1901–1929. doi: 10.1177/0300060516675504

Table 1.

The primary characteristics of endothelial dysfunction [references 4,5,6,17,25,32].

Normal endothelial function Endothelial dysfunction Mechanisms
Normal NO bioavailability and vasodilation ↓NO bioavailability and vasodilation ↓eNOS, eNOS uncoupling, ↑NO breakdown (ROS)
↑Prostacyclin ↓Prostacyclin ↓Prostacyclin synthase
↑EDHF-mediated responses ↓EDHF-mediated responses
Normal vasoconstrictor levels ↑Vasoconstriction ↑ET-1, PGH2 and other endothelium-derived factors
Anti-inflammatory properties Pro-inflammatory properties ↑Adhesion molecules, ↑cytokines
↓Endothelial permeability ↑Endothelial permeability
Anti-thrombotic properties Pro-thrombotic properties ↑PAI-1, vWF, P-selectin, ↑platelet activity
Normal fibrinolytic activity ↓Fibrinolytic activity
↓Oxidative stress ↑Oxidative stress ↑NADPH oxidase, eNOS uncoupling, other enzymes, ↓antioxidant defense
Anti-atherogenic properties Pro-atherogenic properties ↑FFA, ↑LDL oxidation, ↑AGE + above described mechanisms
Normal quantity and quality of EPC ↓Quantity and quality of EPC Weak bone marrow mobilization, ↓proliferation, ↓survival, ↑ROS
Normal vascular structure and angiogenesis Remodelling Changes in growth factors, inflammation, matrix proteins, etc.

EDHF: endothelium-derived hyperpolarizing factor; ROS: reactive oxygen species; PAI-1: plasminogen activator inhibitor-1; vWF: von Willebrand factor; eNOS: endothelial nitric oxide synthase; PGH2: prostaglandin H2; EPC: endothelial progenitor cells; NADPH: nicotinamide adenine dinucleotide phosphate; AGE: advanced glycation end products; LDL: low-density lipoprotein; FFA: free fatty acids.